Tirzepatide produces more weight loss than semaglutide for most people. In the first head-to-head trial, published in 2025, patients on tirzepatide lost an average of 20.2 percent of their body weight at 72 weeks, against 13.7 percent on semaglutide. Semaglutide still has one clear advantage: proven cardiovascular protection in a large outcomes trial. At Nexsis BioHealth in Brickell, Miami, our physicians choose between them based on your labs, your heart health history and how you tolerate the medication, inside a 6-month program priced at $1,800.
Both drugs are weekly injections. Both are FDA approved for chronic weight management in their obesity-labeled forms (Wegovy for semaglutide, Zepbound for tirzepatide). And both are now among the most searched medical treatments in Miami. Here is how they actually differ, and why the better drug on paper is not automatically the better drug for you.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Brand names (weight loss) | Wegovy | Zepbound |
| How it works | GLP-1 receptor agonist | GLP-1 and GIP receptor agonist |
| Dosing | Weekly injection, stepped up to 2.4 mg | Weekly injection, stepped up from 2.5 mg to as high as 15 mg |
| Average weight loss in head-to-head trial | 13.7% at 72 weeks | 20.2% at 72 weeks |
| Proven heart benefit | Yes, 20% fewer major cardiac events in the SELECT trial | Outcomes trial data still maturing |
| Most common side effects | Nausea, constipation, diarrhea | Nausea, constipation, diarrhea |
Semaglutide mimics GLP-1, a gut hormone your body releases after eating. It slows how quickly your stomach empties, signals fullness to the brain, and helps regulate blood sugar. The practical effect most patients describe is that food simply stops occupying their thoughts the way it used to.
Tirzepatide acts on GLP-1 and a second hormone pathway, GIP. That dual action is the main reason it produces more weight loss on average. It also tends to improve blood sugar control slightly more, which matters for patients with insulin resistance or prediabetes.
If you have read about retatrutide, the triple agonist in late-stage trials, that is the next step on this same ladder. It is not FDA approved yet. We explain where it stands in our guide on whether retatrutide is FDA approved.
For years the comparison relied on separate trials run on different patients. That changed with SURMOUNT-5, published in the New England Journal of Medicine in 2025. It enrolled adults with obesity but without type 2 diabetes and assigned them to one drug or the other at the maximum tolerated dose.
After 72 weeks, the tirzepatide group had lost an average of 20.2 percent of body weight. The semaglutide group had lost 13.7 percent. Tirzepatide patients also lost more from the waist. In real terms, for a 220 pound patient, that is roughly 44 pounds versus 30 pounds.
Two caveats belong next to those numbers. Trial averages describe a group, not a person, and plenty of patients do better on semaglutide than the average tirzepatide patient. And trial patients get structured follow-up, which is exactly what many cheaper online programs leave out.
Semaglutide is the only one of the two with a completed cardiovascular outcomes trial in people with obesity. In SELECT, patients with established heart disease and excess weight, but without diabetes, had 20 percent fewer heart attacks, strokes and cardiovascular deaths on semaglutide than on placebo.
For a patient with a history of heart disease, that evidence carries real weight. It is also the drug with the longest real-world track record, which some patients and physicians reasonably prefer.
Both drugs cause the same family of side effects, mostly digestive: nausea, constipation, diarrhea and reduced appetite that can tip into eating too little. They are most noticeable in the first weeks and after each dose increase, which is why both drugs start low and step up slowly.
Both carry the same boxed warning. Neither should be used by anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Both also require care around pancreatitis and gallbladder history. This is one reason a real consultation and lab panel come before any prescription.
One effect gets less attention than it should: rapid weight loss on either drug costs some muscle along with fat. That is why our program tracks body composition with InBody scans rather than scale weight alone. Losing 30 pounds of mostly fat and losing 30 pounds with a large share of muscle are very different outcomes.
Both manufacturers now sell direct to self-pay patients, and the medication generally runs about $200 to $450 per month depending on dose and program. Those prices change often, so confirm current figures before you budget. Insurance coverage for weight loss use exists on some plans but usually requires prior authorization.
The medication is only part of the cost. Supervision, labs, dose management and follow-up are the rest. At Nexsis BioHealth, our Medical Weight Loss program is $1,800 for 6 months and covers the physician consultation, lab review, InBody body composition tracking, GLP-1 medication management and ongoing clinical support. Members of our membership program receive 15 to 20 percent off services.
There is no single right answer, and anyone who picks one drug for every patient is not really choosing. In practice, the decision comes down to a few questions:
Switching later is a normal clinical decision. Starting on one does not lock you out of the other.
Our clinic is at 40 SW 13th St in Brickell, and we see weight loss patients from Coral Gables, Coconut Grove, Downtown Miami, Key Biscayne and across South Florida. Your first visit covers your history, current medications and goals, followed by baseline labs and an InBody scan before anything is prescribed.
Book a weight loss consultation and our physician team will tell you which medication fits your situation, or whether medication is the right route for you at all.
On average, yes. In the SURMOUNT-5 head-to-head trial, tirzepatide produced 20.2 percent average weight loss at 72 weeks versus 13.7 percent for semaglutide. Individual results vary, and semaglutide has proven cardiovascular benefits that tirzepatide has not yet shown in a completed outcomes trial.
Yes. Switching is common, especially for patients who plateau or have trouble with side effects. It should be done under physician supervision, because the new medication is usually restarted at a lower dose and stepped up again.
Their side effect profiles are very similar, mostly nausea, constipation and diarrhea, especially early on and after dose increases. Some patients tolerate one better than the other, which is one reason physicians sometimes switch medications.
Direct self-pay pricing from the manufacturers generally runs about $200 to $450 per month depending on dose, and changes often. At Nexsis BioHealth, the complete 6-month physician-supervised program is $1,800, covering consultation, labs, InBody tracking, medication management and follow-up.
Anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not take either drug. They are also not used during pregnancy, and a history of pancreatitis or gallbladder disease needs careful review. Your physician screens for these at the first consultation.
Most patients notice reduced appetite within the first few weeks. Meaningful weight loss builds over months as the dose is stepped up, which is why our program runs six months with regular body composition checks rather than promising quick results.
This article is for general education and is not medical advice. Treatment decisions at Nexsis BioHealth are made by our licensed physician team after consultation and lab review.
